Search

Our goal of transforming the treatment of neuroendocrine carcinomas

Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).

License deal with A*STAR to develop cancer antibodies

RE-LY-trial-publication-10-year-anniversary

Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers

New indications NexGard, NexGard SPECTRA and Broadline

New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA

Zongertinib positive results non-small cell lung cancer

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

New Partnership to Develop Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis

Performance Indicators

Performance indicators concerning Environment Health and Safety (EHS) are summarized here.

FDA-Fast-Track-chronic-kidney-disease

FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition

CARMELINA-elderly-analysis

CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes

EMPRISE-interim-analysis

Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

EMPERIAL-heart-failure-toplineresults

Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers